Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab Open-Label Extension in Persistent or Chronic ITP
NCT04596995Phase 3Terminated
- Sponsor
- UCB
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, open-label, single-arm trial of rozanolixizumab in primary immune thrombocytopenia (ITP), sponsored by UCB. Primary endpoints: Percentage of Participants With Treatment-emergent Adverse Events and Percentage of Participants With TEAEs Leading to Permanent Withdrawal. Started Jan 2021; status: terminated.
02
Drugs
rozanolixizumab
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04596995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04596995.